Global issues and opportunities for optimized retinoblastoma care

Pediatric Blood and Cancer

Volumn 49, Issue 7 SUPPL., 2007, Pages 1083-1090

  Gallie, Brenda L ^a,f   Zhao, Junyang ^b   Vandezande, Kirk ^c   White, Abigail ^d,e   Chan, Helen S L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Daisy's Eye Cancer Fund   (United Kingdom)

^e SickKids Hospital   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Retinoblastoma; Suppressor genes

Indexed keywords

CARBOPLATIN; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; VINCRISTINE;

CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHILD; CHROMOSOME 16Q; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPED COUNTRY; DIAGNOSTIC IMAGING; DRUG MEGADOSE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; LASER SURGERY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C MYB; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RETINA CELL; RETINOBLASTOMA; REVIEW; STEM CELL; TUMOR SUPPRESSOR GENE; VISION;

GERM-LINE MUTATION; HUMANS; RETINAL NEOPLASMS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN; WORLD HEALTH;

EID: 35648981872     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21350     Document Type: Review

References (67)

1. Gallie B, Erraguntla V, Heon E, et al. Retinoblastoma. In: Taylor D, Hoyt C, editors. Pediatric ophthalmology and strabismus. London, UK: Elsevier; 2004. pp 486-504.
2. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-784.
3. McDaid C, Hartley S, Bagnall AM, et al. Systematic review of effectiveness of different treatments for childhood retinoblastoma. Health Technol Assess 2005;9: iii, ix-x, 1-145.
4. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-646.
5. Richter S, Vandezande K, Chen N, et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 2003;72:253-269.
6. Noorani HZ, Khan HN, Gallie BL, et al. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma (see comments). Am J Hum Genet 1996;59:301-307.
7. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: A way out of a conundrum. BMJ 1995;311:1621-1625.
8. MacCarthy A, Draper GJ, Steliarova-Foucher E, et al. Retino-blastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2092-2102.
9. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
10. Comings DE. A general theory of carcinogenesis. Proc Natl Acad Sci USA 1973;70:3324-3328.
11. Knight LA, Gardner HA, Gallie BL. Segregation of chromosome 13 in retinoblastoma [letter]. Lancet 1978;1:989.
12. Godbout R, Dryja TP, Squire J, et al. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 1983;304:451-453.
13. Dryja TP, Rapaport JM, Joyce JM, et al. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc Natl Acad Sci USA 1986;83:7391-7394.
14. Sippel KC, Fraioli RE, Smith GD, et al. Frequency of somatic and germ-line mosaicism in retinoblastoma: Implications for genetic counseling. Am J Hum Genet 1998;62:610-619.
15. Gallie BL, Ellsworth RM, Abramson DH, et al. Retinoma: Spontaneous regression of retinoblastoma or benign manifestation of the mutation? Br J Cancer 1982;45:513-521.
16. Dimaras H, Coburn B, Pajovic S, et al. Loss of p75 neurotrophin receptor expression accompanies malignant progression to human and murine retinoblastoma. Mol Carcinog 2006;45:333-343.
17. -/- precursor to human retinoblastoma. (Submitted for publication).
18. Corson TW, Gallie BL. One hit, two hits, three hits, more? Cancer Genes Chromosomes Cancer 2007;46:617-634.
19. Corson TW, Huang A, Tsao MS, et al. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005;24:4741-4753.
20. Marchong MN, Chen D, Corson TW, et al. Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma. Mol Cancer Res 2004;2:495-503.
21. Orlic M, Spencer CE, Wang L, et al. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006;45:72-82.
22. Corson TW, Zhu CQ, Lau SK, et al. KIF14 mRNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 2007;13:3229-3334.
23. Bowles E, Corson TW, Bayani J, et al. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 2006;46:118-129.
24. Corson TW, Gallie BL. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 2006;119:1088-1094.
25. Nork TM, Schwartz TL, Doshi HM, et al. Retinoblastoma: Cell of origin. Arch Ophthalmol 1995;113:791-802.
26. Gallie BL, Campbell C, Devlin H, et al. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 1999;59:1731s-1735s.
27. Eagle RC, Jr., Shields JA, Donoso L, et al. Malignant transformation of spontaneously regressed retinoblastoma, retinoma/ retinocytoma variant. Ophthalmology 1989;96:1389-1395.
28. Kiess M, Gill RM, Hamel PA. Expression and, activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation. Cell Growth Differ 1995;6: 1287-1298.
29. Kapic A, Helmbold H, Reimer R, et al. Cooperation between p53 and p130(Rb2) in induction of cellular senescence. Cell Death Differ 2006;13:324-334.
30. Gerlach JH, Kartner N, Bell DR, et al. Multidrug resistance. Cancer Surv 1986;5:25-46.
31. White L. Chemotherapy in retinoblastoma: Current status and future directions. Am J Pediatr Hematol Oncol 1991;13:189-201.
32. Chan HSL, Lu Y, Grogan TM, et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 1997;57:2325-2330.
33. Chan HS, Thorner PS, Haddad G, et al. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991;98:1425-1431.
34. Chan HS, Gallie BL, Munier FL, et al. Chemotherapy for retinoblastoma. Ophthalmol Clin N Am 2005;18:55-63.
35. Murphree AL. Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin N Am 2005;18:41-53.
36. Wilson TW, Chan HS, Moselhy GM, et al. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol 1996;114:1390-1395.
37. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-5910.
38. Krishnakumar S, Mallikarjuna K, Desai N, et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol 2004;88:1521-1526.
39. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444:61-66.
40. Draper GJ, Sanders BM, Brownbill PA, et al. Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. Br J Cancer 1992;66:211-219.
41. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. JNCI 1993;85: 1121-1128.
42. Wong FL, Boice JD, Jr., Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-1267.
43. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma and risk of lung cancer. JNCI 2000;92:2037-2039.
44. Fletcher J. Cytogenetic and experimental models. Curr Opin Oncol 1992;4:659-666.
45. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. JNCI 2004;96:357-363.
46. De Potter P, Shields CL, Shields JA. Clinical variations of trilateral retinoblastoma: A report of 13 cases. J Pediatr Ophthalmol Strabismus 1994;31:26-31.
47. Lueder GT, Judisch GF, Wen BC. Heritable retinoblastoma and pinealoma. Arch Ophthalmol 1991;109:1707-1709.
48. Kivela T. Trilateral retinoblastoma: A meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999;17:1829-1837.
49. Paulino AC. Trilateral retinoblastoma: Is the location of the intracranial tumor important? Cancer 1999;86:135-141.
50. Moll AC, Kuik DJ, Bouter LM, et al. Incidence and survival of retinoblastoma in The Netherlands: A register based study 1862-1995. Br J Ophthalmol 1997;81:559-562.
51. Moll AC, Imhof SM, Schouten-van Meeteren AY, et al. Chemoreduction for retinoblastoma. Arch Ophthalmol 2003;121:1513.
52. Meadows AT, Shields CL. Regarding chemoreduction for retinoblastoma and intracranial neoplasms. Arch Ophthalmol 2004; 122:1570-1571, author reply 1571.
53. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-1909.
54. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-1886.
55. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892.
56. Retsas S. Treatment at random: The ultimate science or the betrayal of Hippocrates? J Clin Oncol 2004;22:5005-5008, discussion 5009-5011.
57. Wang L, Panzarella T, Murphree A, et al. World survey of retinoblastoma classification. Proceedings of the 15th Meeting of the International Society for Genetic Eye Disease, with the 12th International Retinoblastoma Symposium and the 12th International Congress of Oncology. Whistler, Canada; 2005.
58. Ellsworth RM. The practical management of retinoblastoma. Trans Am Ophthalmol Soc 1969;67:462-534.
59. Houdayer C, Gauthier-Villars M, Lauge A, et al. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat 2004;23:193-202.
60. Sahgal A, Millar B, Michaels H, et al. Focal stereotactic external beam radiotherapy as a vision-sparing method for the treatment of peripapillary and perimacular retinoblastoma: Preliminary results. Clin Oncol 2006;18:628-634.
61. NSCAG. National specialist commissioning advisory group annual report 2003-2004; October 2004. Report.
62. Gutteridge W. NSCAG retinoblastoma review report 2004.
63. Red reflex examination in infants. Section on Ophthalmology. American Academy of Pediatrics. Pediatrics 2002;109:980-981.
64. Zilelioglu G, Gunduz K. Ultrasonic findings in intraocular retinoblastoma and correlation with histopathologic diagnosis. Int Ophthalmol 1995;19:71-75.
65. Kaufman LM, Mafee MF, Song CD. Retinoblastoma and simulating lesions. Role of CT, MR imaging and use of Gd-DTPA contrast enhancement. Radiol Clin North Am 1998;36:1101-1117.
66. Beets-Tan RG, Hendriks MJ, Ramos LM, et al. Retinoblastoma: CT and MRI. Neuroradiology 1994;36:59-62.
67. Ainbinder DJ, Haik BG, Frei DF, et al. Gadolinium enhancement: Improved MRI detection of retinoblastoma extension into the optic nerve. Neuroradiology 1996;38:778-781.